RxDoctor Payments Data

Ann Thomas, MD

Family Medicine · Wellington, FLNPI 1639300247

Payments from drug & device makers

$1,155in general payments, 2019–2025

Across 57 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$287
  • Novo Nordisk$194
  • GSK$166
  • AstraZeneca$156
  • Amgen$123
  • Lilly USA, LLC$100
  • plus $131 from 4 others

What the payments were for

  • Food & beverage$1,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences12$287
Novo Nordisk11$194
GSK9$166
AstraZeneca7$156
Amgen7$123
Lilly USA, LLC5$100
Pfizer3$65
Boston Scientific1$31
Abiomed1$18
Insmed, Inc.1$17

How this compares

$1,155 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$90,275
Medicare patients
110
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$80,469
RybelsusSemaglutide51$62,513
EliquisApixaban25$36,231
XareltoRivaroxaban17$23,496
WegovySemaglutide14$19,386
JardianceEmpagliflozin18$17,874
OzempicSemaglutide13$15,580
Repatha SureclickEvolocumab15$8,218
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,179
Atorvastatin Calcium343$3,725
Rosuvastatin Calcium184$2,069
SynthroidLevothyroxine Sodium23$1,988
Fluticasone Propionate192$1,971
Omeprazole119$1,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Wegovy, Ozempic$194$97,47978 claims
GSKTrelegy Ellipta$166$80,469105 claims
PfizerEliquis$65$36,23125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →